Showing CypComp Card for CC02401: Imatinib (CypBoM Training Set)

Record Information
Version1.0
Creation Date2019-07-14 16:54:55 UTC
Last Updated2019-10-01 21:42:04 UTC
CypComp IDCC02401
Compound Information
NameImatinib
Structure ImageKtufnokkbvmgrw uhfffaoysa n
InChIKeyKTUFNOKKBVMGRW-UHFFFAOYSA-N
PubChem ID5291
CypCompound Information
SetCypBoM Training Set
Bonds of Metabolism (BoMs)
CYP1A2CYP2A6CYP2B6CYP2C8CYP2C9CYP2C19CYP2D6CYP2E1CYP3A4
  • Not Available
  • Not Available
  • Not Available
  • Not Available
  • Not Available
  • Not Available
  • Not Available
  • Not Available
  • <7,4;Cleavage;R1>
  • <7,H;Oxidation;R1>
References
  1. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002 May;8(5):935-42. [PubMed:12006504 ]
  2. Novartis Pharmaceuticals (2018) Gleevec(imatinib mesylate) full prescribing information [Link]
Download FileCC02401.sdf